What is the potential role of hepatic arterial infusion chemotherapy in the current armamentorium against colorectal cancer

Journal of Gastrointestinal Oncology

Volumn 3, Issue 2, 2012, Pages 130-138

  Kanat, Ozkän ^a   Gewirtz, Alexandra ^a   Kemeny, Nancy ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adjuvant; Colorectal cancer; Conversion treatment; Hepatic arterial infusion; Liver metastases

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CISPLATIN; DEXAMETHASONE; FIRTECAN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PIRARUBICIN;

ABDOMINAL PAIN; ACUTE PANCREATITIS; AMINOTRANSFERASE BLOOD LEVEL; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTICLE; BILIARY SCLEROSIS; BILIARY TRACT DISEASE; BLEEDING; BONE MARROW DISEASE; BONE MARROW INHIBITION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CATHETER COMPLICATION; CATHETER THROMBOSIS; CHOLECYSTECTOMY; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG ACTIVITY; DRUG ADMINISTRATION ROUTE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG ISOLATION; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEPATIC ARTERIAL INFUSION CHEMOTHERAPY; HEPATOBILIARY DISEASE; HUMAN; HYPOTENSION; KIDNEY ARTERY STENOSIS; LEUKOPENIA; LIVER FUNCTION TEST; LIVER INJURY; LIVER METABOLISM; LIVER METASTASIS; LIVER SURGERY; LIVER TOXICITY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PUMP; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL TIME; TOXIC HEPATITIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84995768512     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.3978/j.issn.2078-6891.2011.025     Document Type: Article

References (64)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
3. Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist 2008;13:51-64.
4. Kingham TP, D'Angelica M, Kemeny NE. Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancer metastases. J Surg Oncol 2010;102:988-95.
5. Kelly RJ, Kemeny NE, Leonard GD. Current strategies using hepatic arterial infusion chemotherapy for the treatment of colorectal cancer. Clin Colorectal Cancer 2005;5:166-74.
6. Kemeny N, Seiter K, Niedzwiecki D, Chapman D, Sigurdson E, Cohen A, et a l. A randomized tr ia l of intrahepat ic infusion of f luorodeoxyuridine with dexamethasone versus f luorodeoxyuridine alone in the treatment of metastat ic colorectal cancer. Cancer 1992;69:327-34.
7. Kemeny N, Conti JA, Cohen A, Campana P, Huang Y, Shi WJ, et al. Phase II study of hepatic arterial f loxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 1994;12:2288-95.
8. Iyer L, Ratain MJ. Clinical pharmacology of camptothecins. Cancer Chemother Pharmacol 1998;42:S31-43.
9. Abigerges D, Chabot GG, Armand JP, Hérait P, Gouyette A, Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995;13:210-21.
10. van Riel JM, van Groeningen CJ, de Greve J, Gruia G, Pinedo HM, Giaccone G. Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver. Ann Oncol 2004;15:59-63.
11. van Riel JM, van Groeningen CJ, Kedde MA, Gall H, Leisink JM, Gruia G, et al. Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study. Clin Cancer Res 2002;8:405-12.
12. Kornmann M, Fakler H, Butzer U, Beger HG, Link KH. Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases. Anticancer Res 2000;20:3259-64.
13. Dzodic R, Gomez-Abuin G, Rougier P, Bonnay M, Ardouin P, Gouyette A, et al. Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model. Anticancer Drugs 2004;15:647-50.
14. Guthoff I, Lotspeich E, Fester C, Wallin I, Schatz M, Ehrsson H, et al. Hepatic arter y infusion using oxaliplatin in combination with 5-f luorouraci l, fol inic acid and mitomycin C: oxal iplat i n pharmacokinetics and feasibility. Anticancer Res 2003;23:5203-8.
15. Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987;107:459-65.
16. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-f luorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987;206:685-93.
17. Hohn DC, Stagg RJ, Friedman MA, Hannigan JF Jr, Rayner A, Ignoffo RJ, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 1989;7:1646-54.
18. Wagman LD, Kemeny MM, Leong L, Terz JJ, Hill LR, Beatty JD, et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 1990;8:1885-93.
19. Martin JK Jr, O'Connell MJ, Wieand HS, Fitzgibbons RJ Jr, Mailliard JA, Rubin J, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990;125:1022-7.
20. Rougier P, Laplanche A, Huguier M, Hay JM, Ollivier JM, Escat J, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases f rom colorecta l ca rcinoma: long-term results of a prospect ive randomized trial. J Clin Oncol 1992;10:1112-8.
21. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 1994;344:1255-60.
22. Lorenz M, Müller HH. Randomized, multicenter trial of f luorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus f luorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000;18:243-54.
23. Kerr DJ, McArdle CS, Ledermann J, Taylor I, Sherlock DJ, Schlag PM, et al. Intrahepatic arterial versus intravenous f luorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 2003;361:368-73.
24. Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006;24:1395-403.
25. Kemeny NE, Melendez FD, Capanu M, Paty PB, Fong Y, Schwartz LH, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2009;27:3465-71.
26. Allen-Mersh TG, Glover C, Fordy C, Mathur P, Quinn H. Randomized trial of regional plus systemic f luorinated pyrimidine compared with systemic f luorinated pyrimidine in treatment of colorectal liver metastases. Eur J Surg Oncol 2000;468-73.
27. Fallik D, Ychou M, Jacob J, Col in P, Seitz JF, Baul ieux J, et al. Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer. Ann Oncol 2003;14:856-63.
28. Mancini R, Tedesco M, Garufi C, Filippini A, Arcieri S, Caterino M, et al. Hepatic arterial infusion (HAI) of cisplatin and systemic fluorouracil in the treatment of unresectable colorectal liver metastases. Anticancer Res 2003;23:1837-41.
29. Shimonov M, Hayat H, Chaitchik S, Brener J, Schachter P, Czerniak A. Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver. Chemotherapy 2005;51:111-5.
30. Fiorentini G, Cantore M, Rossi S, Vaira M, Tumolo S, Dentico P, et al. Hepatic arterial chemotherapy in combination with systemic chemotherapy compared with hepatic arterial chemotherapy alone for liver metastases from colorectal cancer: results of a multi-centric randomized study. In Vivo 2006;707-9.
31. Tsutsumi S, Yamaguchi S, Tsuboi K, Fukasawa T, Tabe Y, Asao T, et al. Hepatic arterial infusion combined with oral UFT/UZEL systemic chemotherapy for unresectable liver metastasis of colorectal cancer. Hepatogastroenterology 2008;55:1419-22.
32. Idelevich E, Greif F, Mavor E, Miller R, Kashtan H, Susmalian S, et al. Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer. Chemotherapy 2009;55:76-82.
33. Goéré D, Deshaies I, de Baere T, Boige V, Malka D, Dumont F, et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg 2010;686-91.
34. Kemeny N, Gonen M, Sullivan D, Schwartz L, Benedetti F, Saltz L, et al. Phase I study of hepatic arterial infusion of f loxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 2001;19:2687-95.
35. Kemeny N, Gonen M, Sullivan D, Schwartz L, Benedetti F, Saltz L, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005;23:4888-96.
36. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309-18.
37. Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2005;23: 4881-7.
38. Boige V, Malka D, Elias D, Castaing M, De Baere T, Goere D, et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 2008;15:219-26.
39. Elias D, Goere D, Boige V, Kohneh-Sharhi N, Malka D, Tomasic G, et al. Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 2007;14:3188-94.
40. Benoist S, Brouquet A, Penna C, Julié C, El Hajjam M, Chagnon S, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006;24:3939-45.
41. Auer RC, White RR, Kemeny NE, Schwartz LH, Shia J, Blumgart LH, et al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 2010;116:1502-9.
42. Gallagher DJ, Capanu M, Raggio G, Kemeny N. Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis. Ann Oncol 2007;18:1995-9.
43. Kern W, Beckert B, Lang N, Stemmler J, Beykirch M, Stein J, et al. Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Ann Oncol 2001;12:599-603.
44. Fiorentini G, Rossi S, Dentico P, Meucci F, Bonechi F, Bernardeschi P, et al. Oxaliplatin hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: a phase I-II clinical study. Anticancer Res 2004;24:2093-6.
45. Mancuso A, Giuliani R, Accettura C, Palma M, D'Auria G, Cecere F, et al. Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer. Anticancer Res 2003;23:1917-22.
46. Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, et al. Multicenter randomized trial of adjuvant f luorouracil and folinic acid compared with surger y alone af ter resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006;24:4976-82.
47. Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008;26:4906-11.
48. Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C, et al. A randomized phase III study comparing adjuvant [5-f] luorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 2009;1964-70.
49. Power DG, Kemeny NE. Role of adjuvant therapy after resection of colorectal cancer liver metastases. J Clin Oncol 2010;28:2300-9.
50. Kemeny MM, Adak S, Gray B, Macdonald JS, Smith T, Lipsitz S, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy- an intergroup study. J Clin Oncol 2002;20:1499-505.
51. Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Eng J Med 1999;341:2039-48.
52. Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Eng J Med 2005;352:734-5.
53. Lygidakis NJ, Sgourakis G, Vlachos L, Raptis S, Safioleas M, Boura P, et al. Metastatic liver disease of colorectal origin: the value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepatogastroenterology 2001;48:1685-91.
54. Kemeny N, Jarnagin W, Gonen M, Stockman J, Blumgart L, Sperber D, et al. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. J Clin Oncol 2003;21:3303-9.
55. Kemeny N, Capanu M, D'Angelica M, Jarnagin W, Haviland D, Dematteo R, et al. Phase I trial of adjuvant hepatic arterial infusion (HAI) with f loxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol 2009;20:1236-41.
56. Kemeny NE, Jarnagin WR, Capanu M, Fong Y, Gewirtz AN, Dematteo RP, et al. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol 2011;29:884-9.
57. Alberts SR, Roh MS, Mahoney MR, O'Connell MJ, Nagorney DM, Wagman L, et al. Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66. J Clin Oncol 2010;28:853-8.
58. Hubbard JM, Alberts SR. Treatment of liver-limited metastatic colorectal cancer. Cancer J 2010;16:235-40.
59. Barnett KT, Malafa MP. Complications of hepatic artery infusion: a review of 4580 reported cases. Int J Gastrointest Cancer 2001;30:147
60. Allen PJ, Nissan A, Picon AI, Kemeny N, Dudrick P, Ben-Porat L, et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg 2005;201:57-65.
61. Power DG, Kemeny NE. The role of f loxuridine in metastatic liver disease. Mol Cancer Ther 2009;8:1015-25.
62. Cohen AD, Kemeny NE. An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist 2003;8:553-66.
63. Davidson BS, Izzo F, Chase JL, DuBrow RA, Patt Y, Hohn DC, et al. Alternating f loxuridine and 5-f luorouracil hepatic arterial chemotherapy for colorectal liver metastases minimizes biliary toxicity. Am J Surg 1996;172:244-7.
64. Stagg RJ, Venook AP, Chase JL, Lewis BJ, Warren RS, Roh M, et al. Alternating hepatic intra-arterial f loxuridine and f luorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. J Natl Cancer Inst 1991;83:423-8.